Cartesian Therapeutics, Inc. Common Stock (RNAC) Stock
Key stats
- Market cap
- $209.86M
- Price / Earnings ratio
- -1.6x
- EPS (TTM)
- -$4.94
- Volume
- Loading
- 52-week high
- $11.00
- 52-week low
- $5.60
Source: third-party data provider, as of November 13, 2026
Compare with RNAC
Recent news

New Strong Sell Stocks for July 1st
New Strong Sell Stocks for July 1st
RNAC

Substantial Insider Buying: American Express, Asana, and More
Substantial Insider Buying: American Express, Asana, and More
RNAC

Insider Buying Slows, but Not for 7 These Buyers
Insider Buying Slows, but Not for 7 These Buyers
RNAC
Technical indicators
- RSI 14
- 50.23
- MACD 12/26/9
- -0.05
- EMA 9 of MACD
- -0.17
- MACD histogram
- 0.12
- SMA 50
- $7.25
- Price below SMA 50
- EMA 50
- $7.20
- Price below EMA 50
- SMA 200
- $7.62
- Price below SMA 200
- EMA 200
- $7.46
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

New Strong Sell Stocks for July 1st
New Strong Sell Stocks for July 1st
RNAC

Substantial Insider Buying: American Express, Asana, and More
Substantial Insider Buying: American Express, Asana, and More
RNAC

Insider Buying Slows, but Not for 7 These Buyers
Insider Buying Slows, but Not for 7 These Buyers
RNAC
About Cartesian Therapeutics, Inc. Common Stock
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering cell therapy for the treatment of autoimmune diseases. The company uses technology and a manufacturing platform to introduce mRNA into cells to provide a therapeutic effect to patients suffering from a variety of autoimmune conditions. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Carsten Brunn Ph.D. | President, CEO & Chairman of the Board | 1971 |
| Mr. Blaine T. Davis | Chief Financial Officer | 1974 |
| Dr. Emily English Ph.D. | Chief Operating Officer | 1980 |
| Ms. June Seymour | Chief Accounting Officer | 1978 |
| Mr. Matthew Bartholomae J.D. | General Counsel & Secretary | — |
| Dr. Peter G. Traber M.D. | Head of R&D | 1955 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 50.23
- MACD 12/26/9
- -0.05
- EMA 9 of MACD
- -0.17
- MACD histogram
- 0.12
- SMA 50
- $7.25
- Price below SMA 50
- EMA 50
- $7.20
- Price below EMA 50
- SMA 200
- $7.62
- Price below SMA 200
- EMA 200
- $7.46
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $25.00
- Average
- $34.33
- High
- $40.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +2.4 | -23.4 | +17.9 | -22.5 | -10.1 | +8.7 |



